Circio Holding ASA (OSL:CRNA) ROCE % : 0.00% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Circio Holding ASA ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Circio Holding ASA's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.00%.

Circio Holding ASA ROCE % Historical Data

The historical data trend for Circio Holding ASA's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Circio Holding ASA ROCE % Chart

Circio Holding ASA Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-33.20

-23.09

-18.77

-166.80

Circio Holding ASA Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial															-23.68	-16.67	-625.45	-	-

Circio Holding ASA ROCE % Calculation

Circio Holding ASA's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-107.179	/	( ( (100.414 - 40.415)	+	(28.135 - 124.471) )	/ 2 )
	=	-107.179	/	( (59.999	+	-96.336)	/ 2 )
	=	-107.179	/	-18.1685
	=	589.92 %

Circio Holding ASA's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	0	/	( ( (49.938 - 59.262)	+	(28.135 - 124.471) )	/ 2 )
	=	0	/	( ( -9.324	+	-96.336 )	/ 2 )
	=	0	/	-52.83
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Circio Holding ASA (OSL:CRNA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Circio Holding ASA ROCE % Related Terms

Thank you for viewing the detailed overview of Circio Holding ASA's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Circio Holding ASA (OSL:CRNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Circio Holding ASA (OSL:CRNA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

TA50:Germany

Address

Vollsveien 19, Lysaker, Oslo, NOR, 1366

Website

https://www.circio.com

Circio Holding ASA is a clinical-stage company. It is focused on developing and commercializing immuno-oncology therapies to target treatment-resistant solid tumors. Its product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to infect cancer cells and activate the immune system to fight cancer. It includes the development and implementation with the purpose of developing targeted immunotherapy treatments for cancer patients.

Circio Holding ASA (OSL:CRNA) Headlines

No Headlines